3-甲砜基甲苯 | 10355-06-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-甲砜基甲苯
• 英文名称: methyl 3-methylphenyl sulfone
• 英文别名: 1-methyl-3-(methylsulfonyl)benzene；Methyl m-tolyl sulfone；Methyl-m-tolyl-sulfon；1-methyl-3-methylsulfonylbenzene
• CAS: 10355-06-3
• 化学式: C₈H₁₀O₂S
• mdl: MFCD03789191
• 分子量: 170.232
• InChiKey: HWCMIABYHBVAJW-UHFFFAOYSA-N

物化性质

• 熔点：
  34-35 °C(Solv: ligroine (8032-32-4))
• 沸点：
  149 °C(Press: 7 Torr)
• 密度：
  1.154±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2904100000
• 包装等级：
  III
• 危险类别：
  9
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P310,P362+P364,P403+P233,P501
• 危险品运输编号：
  3077
• 危险性描述：
  H315,H318,H335,H411
• 储存条件：
  室温密封，干燥保存。

反应信息

• 作为反应物：
  描述：

  3-甲砜基甲苯 在 正丁基锂 、 对甲苯磺酰叠氮 、 三乙胺 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 10.5h， 生成 1-diazo-1-(3-methylphenylsulfonyl)-5-hexen-2-one
  参考文献：
  名称：

  Studies on the structure–enantioselectivity relationships in the catalytic asymmetric intramolecular cyclopropanation reaction of α-diazo-β-keto sulfones possessing a methyl-substituted phenyl group

  摘要：

  This manuscript describes studies on structure-enantioselectivity relationships in the catalytic asymmetric intramolecular cyclopropanation (IMCP) reaction of alpha-diazo-beta-keto sulfones possessing a methyl-substituted phenyl group. Enantioselectivity of the IMCP reaction of the alpha-diazo-beta-keto sulfones was varied by the position of a methyl group on the pheny] group in the substrate, and the 2,3-dimethylphenyl sulfone 11h provided the product 12h in 95% yield with 93% ee. This yield is superior to that of the substrate with a mesityl sulfone 11b, and the product 12h is useful because alkylation of its cyclopropane-opened P-keto sulfone derivative 15h provides the C-alkylated product as a major product. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2006.10.046
• 作为产物：
  描述：

  1-甲基-3-(甲硫基)苯 在 水 作用下， 以 乙腈 为溶剂， 以78%的产率得到3-甲砜基甲苯
  参考文献：
  名称：

  无支持电解质的亚砜、砜和亚砜亚胺的流动电合成

  摘要：

  已开发出一种用于将硫化物选择性氧化为亚砜和砜以及将亚砜选择性氧化为N-氰基亚砜亚胺的有效电化学流动工艺。总共合成了69 个亚砜、砜和N-氰基亚砜亚胺的例子，产率高，电流效率高。该合成通过支持无电解质、全自动电化学方案得到辅助和促进，该方案突出了流动电解的优势。

  DOI：

  10.1021/acs.joc.1c00860

文献信息

• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GLAXOSMITHKLINE LLC

  公开号：US20150152108A1

  公开（公告）日：2015-06-04

  The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本发明涉及新型取代桥式脲化合物，相应的相关类似物，药物组合物以及其使用方法。本发明的抑制素调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾病，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红有关的疾病或疾病，以及那些会受益于增加线粒体活性的疾病或疾病。本发明还涉及包含抑制素调节化合物与另一治疗剂组合的组合物。
• [EN] PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF<br/>[FR] INHIBITEURS DE LA PRMT5 CONTENANT UNE DIHYDRO- OU TÉTRAHYDRO-ISOQUINOLÉINE ET LEURS UTILISATIONS
  申请人：EPIZYME INC

  公开号：WO2014100730A1

  公开（公告）日：2014-06-26

  Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5- mediated disorders are also described.

  本文描述了式（A）的化合物，其药学上可接受的盐以及药物组合物。本发明的化合物对抑制PRMT5活性是有用的。还描述了利用这些化合物治疗PRMT5介导的疾病的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• [EN] DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES<br/>[FR] DÉRIVÉS D'AMIDES D'ACIDE 6,7-DIHYDRO-5H-IMIDAZO[1,2-A]IMIDAZOLE-3-CARBOXYLIQUE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010141273A1

  公开（公告）日：2010-12-09

  Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

  6,7-二氢-5H-咪唑[1,2-a]咪唑-3-羧酸酰胺的衍生物对CAMs和白细胞整合素的相互作用具有良好的抑制作用，因此在炎症性疾病的治疗中很有用。
• [EN] COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS<br/>[FR] AGENTS PHARMACEUTIQUES EN COMBINAISON EN TANT QU'INHIBITEURS DE RSV
  申请人：ENANTA PHARM INC

  公开号：WO2019067864A1

  公开（公告）日：2019-04-04

  The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.

  本发明涉及用于治疗呼吸道合胞病毒（RSV）感染的药物剂，该药物剂可以单独或连续给予受试者，治疗包括给予一种有效抑制RSV功能的化合物以及具有抗RSV活性的另一种化合物或化合物组合。

表征谱图